查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1529797

糖尿病神经病变管理市场规模、份额、趋势分析报告：按设备、应用、最终用途、地区和细分市场预测，2024-2030 年

Diabetic Neuropathy Management Market Size, Share & Trends Analysis Report By Devices (Electrical stimulation, Neuro Stimulation Devices), By Application (Peripheral Neuropathy), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 220 Pages | 商品交期: 2-10个工作天内

价格

市场规模及趋势

2023年，糖尿病神经病变治疗的全球市场规模估计为26.2亿美元，预计2024年至2030年复合年增长率为5.8%。推动市场成长的主要因素包括糖尿病盛行率增加、老年人口增加、技术进步、研发活动增加以及产品核可数量增加。根据美国疾病管制与预防中心（CDC）的统计，大约有11.6%的美国，即3840万美国患有糖尿病，估计其中一半人在一生中的某个时刻会患上糖尿病性神经病变。是。

糖尿病的高盛行率是推动市场成长的主要因素。如果不加以控制，糖尿病会导致各种严重的併发症，包括週边神经病变。根据国际糖尿病联盟 (IDF) 的数据，2021 年全球有 5.37 亿成年人患有糖尿病，预计到 2040 年这一数字将跃升至 6.42 亿。糖尿病的盛行率在全球范围内不断增加，尤其是在低收入和中等收入国家。 2021 年，西太平洋、南亚和欧洲的成人糖尿病患者人数将最多，分别为 1.67 亿、8,800 万和 5,900 万人。

此外，更容易患糖尿病神经病变的老年人数量显着增加。由于长期糖尿病、神经再生能力下降以及加剧神经病变症状的合併症等因素，老年人口尤其容易受到影响。随着世界人口老化，世界卫生组织（WHO）预测，到2030年，60岁以上的人口数量将增加到六分之一，从2020年的10亿增加到最近的14亿。到2050年，全球60岁及以上人口预计将增加一倍，达到21亿，80岁以上人口预计将增加两倍，达到4.26亿。这些人口变化预计将增加糖尿病和周边神经病变等慢性疾病的可能性，从而增加老年人糖尿病神经病变的风险。

糖尿病神经病变管理市场的成长是由各种脑部影像技术的使用所推动的，例如电刺激设备、神经刺激设备和神经传导测试设备，这些技术为功能性神经病变、週边神经病变和自主神经病变。此外，製造商在关键应用领域争夺技术进步和产品核可正在推动市场向前发展。 2023 年 10 月，波士顿科学公司宣布用于治疗疼痛性糖尿病週边神经病变(PDN) 的脊髓刺激设备脊髓刺激设备Wavelighter Alpha 脊髓刺激器 (SCS) 已获得核准，PDN 是併发症。这一扩大的适应症使波士顿科学公司在不断成长的 PDN 市场上与雅培 (Abbott)、美敦力(Medtronic) 和 Nebro 竞争。

「使用 SCS 来支持一部分糖尿病患者是世界上成长最快的慢性疾病之一的重要进步。

这种扩大的适应症再次证明了我们致力于提供强大的介入性疼痛解决方案组合的承诺，为医生提供更多的治疗选择，以减轻患者的疼痛。 」

吉姆‧卡西迪 (Jim Cassidy)，波士顿科学公司神经调节部总裁。

政府和私人组织为提高意识和治疗神经病变而采取的几项措施预计将有助于市场成长。例如，2022 年 5 月，Averitas Pharma 在美国进行了 PDPN 疾病宣传活动，旨在提高人们对患有疼痛的糖尿病週边神经病变(PDPN) 患者的重大未满足医疗需求的认识。该宣传活动将包括患者调查、教育材料和媒体参观，以提高对该疾病的认识并鼓励患者接受适当的治疗。

「这项独特的比赛旨在了解患者如何表达糖尿病足神经疼痛。

透过用患者自己的话重新定义症状，糖尿病週边神经神经病变患者和他们的医疗保健提供者可以使用通用的语言来讨论症状，改善诊断、疾病管理和潜在的解决方案，目标是促进围绕政策的更富有成效的对话。 」

Lizandra Marcondes 博士，Averitas Pharma 医疗事务主管。

医疗技术的创新大大改善了糖尿病神经病变的诊断、监测和治疗。从能够早期检测的先进诊断影像技术到新的药物传输系统和神经调节疗法，这些技术突破正在重塑神经病变管理的模式。此外，电神经刺激设备与远端医疗和远端监控解决方案的整合正在改善获得专业护理的机会，特别是对于农村和服务欠缺地区的患者。例如，2022年7月，FDA批准了DyAnsys的First Relief经皮神经电刺激（PENS）装置，用于治疗糖尿病週边神经病变引起的慢性、顽固性疼痛。该设备提供连续的低电平电流脉衝，并放置在耳后。这项核准基于临床研究，该研究表明使用 First Relief 的患者可显着降低疼痛强度并改善振动感知、失眠和焦虑等次要终点。该装置为患有与糖尿病週边神经病变相关的神经病变疼痛的患者提供了非药物、非麻醉性治疗选择。

我们很高兴 FDA 批准了 First Relief，使我们能够使用这种经过验证的设备来治疗与糖尿病神经病变相关的疼痛患者。

First Relief 提供不涉及药物或麻醉剂的重要治疗选择。 」

DyAnsys 执行长 Srini Nageshwar。

糖尿病神经病变日益增加的经济负担导致该领域的医疗保健支出增加。政府和医疗机构正在分配更多资源来有效管理这种疾病，并认识到早期疗育和综合护理的长期成本效益。使用人工智慧开发非侵入性诊断工具将增强早期发现并带来更及时、更有效的治疗。 2023 年 10 月，加州大学圣地牙哥分校 (UCSD) 的研究人员获得了 360 万美元的津贴，用于开发一种新的糖尿病神经病变诊断和治疗组合。该计划旨在建立一种整合先进诊断工具和标靶治疗的综合方法。此外，随着新药、设备和治疗方法的核准不断增加，糖尿病神经病变管理的监管环境也不断发展。

糖尿病神经病变管理全球市场报告细分

该报告预测了全球、区域和国家层面的收益成长，并对2018年至2030年各子区隔的最新行业趋势进行了分析。在这项研究中，Grand View Research 根据设备、应用、最终用途和区域对全球糖尿病神经病变管理市场报告进行了细分：

  • 设备展望（销售，2018-2030 年）。
  • 电刺激设备。
  • 神经刺激设备。
  • 神经传导测试设备。
  • 其他设备。
  • 应用前景（销量，2018-2030）。
  • 週边神经病变。
  • 自主神经病变。
  • 近端神经病变。
  • 单神经炎。
  • 最终用途展望（收益，百万美元，2018-2030 年）。
  • 医院。
  • 家庭保健。
  • 其他最终用途。
  • 区域展望（收入，2018-2030）。
  • 北美。

美国。

加拿大

墨西哥

  • 欧洲

英国

德国

法国

义大利

西班牙

丹麦

瑞典

挪威

  • 亚太地区

日本

中国

印度

澳洲

泰国

韩国

  • 拉丁美洲

巴西

阿根廷

  • 中东和非洲

南非

沙乌地阿拉伯

阿拉伯聯合大公国

科威特

目录

第一章调查方法与范围

第 2 章执行摘要

第三章糖尿病神经病变管理市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • 糖尿病神经病变管理市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第 4 章 糖尿病神经病变管理市场：设备评估与趋势分析

  • 细分仪表板
  • 全球糖尿病神经病变治疗器材市场波动分析
  • 2018-2030 年全球糖尿病神经病变治疗市场规模与趋势分析（按设备）
  • 电刺激设备
  • 神经刺激设备
  • 神经传导测试仪
  • 其他设备

第五章糖尿病神经病变管理市场：应用估计与趋势分析

  • 细分仪表板
  • 全球糖尿病神经病变管理应用市场波动分析
  • 2018-2030 年全球糖尿病神经病变管理市场规模及趋势分析（按应用）
  • 週边神经病变
  • 自主神经病变
  • 近端神经病变
  • 神经病变（局部神经病变）

第六章糖尿病神经病变管理市场：最终用途估计与趋势分析

  • 细分仪表板
  • 全球糖尿病神经病变管理最终用途市场波动分析
  • 2018-2030 年全球糖尿病神经病变管理市场规模与趋势分析（依最终用途）
  • 医院
  • 家庭保健
  • 其他最终用户

第七章糖尿病神经病变管理市场：按设备、应用和最终用途进行的区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 2023年主要企业市场占有率分析
  • Company Position Analysis
  • 公司分类（新兴企业、创新企业、领导者）
  • 公司简介
    • Medtronic
    • NEVRO CORP.
    • NeuroMetrix, Inc.
    • Abbott
    • Boston Scientific Corporation
    • Neuralace
    • Fremslife SrlPI
    • DyAnsys Inc.
    • IMPETO MEDICAL
Product Code: GVR-4-68040-361-8

Market Size & Trends

The global diabetic neuropathy management market size was estimated at USD 2.62 billion in 2023 and is expected to grow at a CAGR of 5.8% from 2024 to 2030. Major factors contributing to the market growth include the growing prevalence of diabetes, the rising geriatric population, technological advancements, increased in R&D activities, and the increase in number of product approvals. According to Centers for Disease Control and Prevention (CDC) statistics, approximately 11.6% of the U.S. population, or 38.4 million Americans, live with diabetes and are estimated that half of these individuals are likely to develop diabetic neuropathy at some point during their lifetime.

High prevalence of diabetes is the major factor driving the market growth. Diabetes, when left unmanaged, can lead to a range of serious complications, including peripheral neuropathy. According to the International Diabetes Federation (IDF), 537 million adults worldwide lived with diabetes in 2021, it further states that the number is expected to surge to 642 million by 2040. The prevalence of diabetes is increasing globally, with the most significant rises observed in low- and middle-income countries. The Western Pacific, South Asia, and Europe had the highest numbers of adults living with diabetes in 2021, at 167 million, 88 million, and 59 million respectively.

Furthermore, there is a notable increase in the number of elderly individuals prone to developing diabetic neuropathy. The geriatric population is particularly vulnerable due to factors such as longer diabetes duration, decreased nerve regeneration capacity, and comorbidities that can exacerbate neuropathic symptoms. As the global population ages, the World Health Organization (WHO) predicts that the number of people aged 60 years and older will increase to 1 in 6 by 2030, rising from 1 billion in 2020 to 1.4 billion recently. The global population of people aged 60 years, and older is expected to double to 2.1 billion by 2050, with individuals aged 80 years or older set to triple to 426 million. This demographic shift is expected to lead to a higher chances of chronic conditions like diabetes and peripheral neuropathy, increasing the risk of diabetic neuropathy among seniors.

The diabetic neuropathy management market growth is anticipated to be driven by the availability of various brain imaging technologies, including electrical stimulation devices, neuro stimulation devices, nerve conduction testing devices, which offer applications for both functional and peripheral neuropathy and autonomic neuropathy. Additionally, technological advancements and manufacturers competing for product approval in key application areas drive the market forwards. In October 2023, Boston Scientific received FDA approval for its spinal cord stimulation device WaveWriter Alpha Spinal Cord Stimulator (SCS) to treat painful diabetic peripheral neuropathy (PDN), a complication of diabetes affecting the legs and feet. This expanded indication positions Boston Scientific to compete with Abbott, Medtronic and Nevro in the growing PDN market.

"The use of SCS to support a subset of the diabetes population is an important advancement for one of the fastest growing chronic conditions in the world.

This expanded indication is another testament to our commitment to delivering a robust portfolio of interventional pain solutions that provides physicians with more treatment choices to help their patients find relief."

Jim Cassidy, president of Neuromodulation at Boston Scientific.

Several initiatives undertaken by the government and private organizations for the awareness and treatment of neuropathy are expected to contribute to market growth. For instance, in May 2022, the US PDPN Disease Awareness Campaign, conducted by Averitas Pharma, aims to raise awareness about the significant unmet medical needs of patients with painful diabetic peripheral neuropathy (PDPN). This campaign involves patient-focused surveys, educational materials, and media tours to increase disease awareness and encourage patients to seek appropriate treatment.

"We launched this unique contest in the community to better understand how patients describe diabetic nerve pain of their feet in their own terms.

By redefining the symptoms using their own words, our goal is to help diabetic peripheral neuropathy patients and their health care providers start using common language to talk about their symptoms, fostering more productive conversations around diagnosis, disease management and potential solutions."

Dr. Lizandra Marcondes, Head Medical Affairs Averitas Pharma.

Innovations in medical technology have significantly improved the diagnosis, monitoring, and treatment of diabetic neuropathy. From advanced imaging techniques that allow for early detection to novel drug delivery systems and neuromodulation therapies, these technological breakthroughs are reshaping the landscape of neuropathy management. Additionally, the integration of telemedicine and remote monitoring solutions and electrical neurostimulation devices has enhanced access to specialized care, particularly for patients in rural or underserved areas. For instance, July 2022, the FDA cleared the First Relief percutaneous electrical neurostimulation (PENS) device by DyAnsys for the treatment of chronic, intractable pain from diabetic peripheral neuropathy. The device delivers continuous pulses of low-level electrical current and is placed behind the ear. The approval was based on a clinical study that showed patients treated with First Relief experienced a significant reduction in pain intensity, as well as improvements in secondary endpoints like vibration perception, insomnia, and anxiety. The device offers a non-drug, non-narcotic treatment option for patients suffering from neuropathic pain associated with diabetic peripheral neuropathy.

''We are excited to have the FDA clearance of First Relief so that this device, which has been proven effective, can now be used to treat patients who have been experiencing pain related to diabetic neuropathy.

First Relief offers a significant treatment option without drugs or narcotics."

DyAnsys CEO Srini Nageshwar.

The growing economic burden of diabetic neuropathy has led to increased healthcare spending in this area. Governments and healthcare organizations are allocating more resources to manage this condition effectively, recognizing the long-term cost benefits of early intervention and comprehensive care. The development of non-invasive diagnostic tools using AI will enhance early detection, leading to more timely and effective treatments. In October 2023, researchers at the University of California, San Diego (UCSD) have received a grant of USD3.6 million to develop a novel combination of diagnosis and treatment for diabetic neuropathy. This project aims to create a comprehensive approach that integrates advanced diagnostic tools with targeted therapies. Further the regulatory landscape for diabetic neuropathy management is evolving, with an uptick in the approval of new drugs, devices, and treatment modalities.

Global Diabetic Neuropathy Management Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global diabetic neuropathy management market report based on devices, application, end-use, and region:

  • Devices Outlook (Revenue, USD Million, 2018 - 2030)
  • Electrical Stimulation Devices
  • Neuro Stimulation Devices
  • Nerve Conduction Testing Devices
  • Other Devices
  • Application Outlook (Revenue, USD Million, 2018 - 2030)
  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Mononeuropathy
  • End-use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
  • Home Healthcare
  • Other End-use
  • Regional Outlook (Revenue, USD Million, 2018 - 2030)
  • North America

U.S.

Canada

Mexico

  • Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

  • Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

  • Latin America

Brazil

Argentina

  • Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Device
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Device outlook
    • 2.2.2. Application outlook
    • 2.2.3. Modality outlook
    • 2.2.4. End use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Diabetic Neuropathy Management Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. High prevalence of diabetes and associated disorders
      • 3.2.1.2. Technological advancements
      • 3.2.1.3. Increase in R&D activities
      • 3.2.1.4. Increasing healthcare expenditure
      • 3.2.1.5. Untapped opportunities in developing economies
      • 3.2.1.6. Increase in number of product approvals
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High-cost barrier
      • 3.2.2.2. Lack of skilled professionals
      • 3.2.2.3. Stringent regulatory approvals
  • 3.3. Diabetic Neuropathy Management Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Diabetic Neuropathy Management Market: Device Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Diabetic Neuropathy Management Device Market Movement Analysis
  • 4.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by Device, 2018 to 2030 (USD Million)
  • 4.4. Electrical Stimulation Devices
    • 4.4.1. Electrical stimulation devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Neuro Stimulation Devices
    • 4.5.1. Neuro stimulation devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Nerve Conduction Testing Devices
    • 4.6.1. Nerve conduction testing devices market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Devices
    • 4.7.1. Other devices market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Neuropathy Management Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Diabetic Neuropathy Management Application Market Movement Analysis
  • 5.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Peripheral Neuropathy
    • 5.4.1. Peripheral neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Autonomic Neuropathy
    • 5.5.1. Autonomic neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Proximal Neuropathy
    • 5.6.1. Proximal neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Mononeuropathy (focal neuropathy)
    • 5.7.1. Mononeuropathy (focal neuropathy) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Neuropathy Management Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Diabetic Neuropathy Management End Use Market Movement Analysis
  • 6.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Hospitals
    • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Home Healthcare
    • 6.5.1. Diagnostic imaging centers market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other End Users
    • 6.6.1. Others end users market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Diabetic Neuropathy Management Market: Regional Estimates & Trend Analysis By Devices, Application, End Use

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Competitive scenario
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Reimbursement structure
      • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Reimbursement structure
      • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Reimbursement structure
      • 7.5.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Competitive scenario
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Reimbursement structure
      • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Reimbursement structure
      • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Reimbursement structure
      • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Reimbursement structure
      • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Reimbursement structure
      • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Reimbursement structure
      • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Reimbursement structure
      • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Competitive scenario
      • 7.6.8.3. Regulatory framework
      • 7.6.8.4. Reimbursement structure
      • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Competitive scenario
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Reimbursement structure
      • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Reimbursement structure
      • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Reimbursement structure
      • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Competitive scenario
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Reimbursement structure
      • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Competitive scenario
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Reimbursement structure
      • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Competitive scenario
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Reimbursement structure
      • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Competitive scenario
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Reimbursement structure
      • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Reimbursement structure
      • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Competitive scenario
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. Reimbursement structure
      • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Competitive scenario
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Reimbursement structure
      • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Competitive scenario
      • 7.9.3.3. Regulatory framework
      • 7.9.3.4. Reimbursement structure
      • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Competitive scenario
      • 7.9.4.3. Regulatory framework
      • 7.9.4.4. Reimbursement structure
      • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share analysis, 2023
  • 8.4. Company Position Analysis
  • 8.5. Company Categorization (Emerging Players, Innovators and Leaders
  • 8.6. Company Profiles
    • 8.6.1. Medtronic
      • 8.6.1.1. Company overview
      • 8.6.1.2. Financial performance
      • 8.6.1.3. Device benchmarking
      • 8.6.1.4. Strategic initiatives
    • 8.6.2. NEVRO CORP.
      • 8.6.2.1. Company overview
      • 8.6.2.2. Financial performance
      • 8.6.2.3. Device benchmarking
      • 8.6.2.4. Strategic initiatives
    • 8.6.3. NeuroMetrix, Inc.
      • 8.6.3.1. Company overview
      • 8.6.3.2. Financial performance
      • 8.6.3.3. Device benchmarking
      • 8.6.3.4. Strategic initiatives
    • 8.6.4. Abbott
      • 8.6.4.1. Company overview
      • 8.6.4.2. Financial performance
      • 8.6.4.3. Device benchmarking
      • 8.6.4.4. Strategic initiatives
    • 8.6.5. Boston Scientific Corporation
      • 8.6.5.1. Company overview
      • 8.6.5.2. Financial performance
      • 8.6.5.3. Device benchmarking
      • 8.6.5.4. Strategic initiatives
    • 8.6.6. Neuralace
      • 8.6.6.1. Company overview
      • 8.6.6.2. Financial performance
      • 8.6.6.3. Device benchmarking
      • 8.6.6.4. Strategic initiatives
    • 8.6.7. Fremslife S.r.l. P.I.
      • 8.6.7.1. Company overview
      • 8.6.7.2. Financial performance
      • 8.6.7.3. Device benchmarking
      • 8.6.7.4. Strategic initiatives
    • 8.6.8. DyAnsys Inc.
      • 8.6.8.1. Company overview
      • 8.6.8.2. Financial performance
      • 8.6.8.3. Device benchmarking
      • 8.6.8.4. Strategic initiatives
    • 8.6.9. IMPETO MEDICAL
      • 8.6.9.1. Company overview
      • 8.6.9.2. Financial performance
      • 8.6.9.3. Device benchmarking
      • 8.6.9.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviation
  • Table 3 North America diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
  • Table 4 North America diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 5 North America diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 6 North America diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 7 U.S diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 8 U.S diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 9 U.S diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 10 Canada diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 11 Canada diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 12 Canada diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 13 Mexico diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 14 Mexico diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 15 Mexico diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 16 Europe diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
  • Table 17 Europe diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 18 Europe diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 19 Europe diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 20 UK diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 21 UK diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 22 UK diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 23 Germany diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 24 Germany diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 25 Germany diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 26 France diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 27 France diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 28 France diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 29 Italy diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 30 Italy diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 31 Italy diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 32 Denmark diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 33 Denmark diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 34 Denmark diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 35 Sweden diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 36 Sweden diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 37 Sweden diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 38 Norway diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 39 Norway diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 40 Norway diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 45 Japan diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 46 Japan diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 47 Japan diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 48 China diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 49 China diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 50 China diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 51 India diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 52 India diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 53 Australia diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 54 Australia diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 55 Australia diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 56 South Korea diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 57 South Korea diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 58 South Korea diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 59 Thailand diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 60 Thailand diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 61 Thailand diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 62 Latin America diabetic neuropathy management market, By Country, 2018 - 2030 (USD Million)
  • Table 63 Latin America diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 64 Latin America diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 65 Latin America diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 66 Brazil diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 67 Brazil diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 68 Brazil diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 69 Argentina diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 70 Argentina diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 71 Argentina diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 72 Middle East & Africa diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
  • Table 73 Middle East & Africa diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 74 Middle East & Africa diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 75 Middle East & Africa diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 76 South Africa diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 77 South Africa diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 78 South Africa diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 79 Saudi Arabia diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 80 Saudi Arabia diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 82 UAE diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 83 UAE diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 84 UAE diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
  • Table 85 Kuwait diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
  • Table 86 Kuwait diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
  • Table 87 Kuwait diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value - chain - based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Diabetic neuropathy management market: market outlook
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Penetration and growth prospect mapping
  • Fig. 17 Industry value chain analysis
  • Fig. 18 Diabetic neuropathy management market driver impact
  • Fig. 19 Diabetic neuropathy management market restraint impact
  • Fig. 20 Diabetic neuropathy management market: Device movement analysis
  • Fig. 21 Diabetic neuropathy management market: Device outlook and key takeaways
  • Fig. 22 Electrical stimulation devices market estimates and forecast, 2018 - 2030
  • Fig. 23 Neuro stimulation devices market estimates and forecast, 2018 - 2030
  • Fig. 24 Nerve conduction testing devices market estimates and forecast, 2018 - 2030
  • Fig. 25 Other devices market estimates and forecast, 2018 - 2030
  • Fig. 26 Diabetic neuropathy management market: Application movement analysis
  • Fig. 27 Diabetic neuropathy management market: Application outlook and key takeaways
  • Fig. 28 Peripheral neuropathy market estimates and forecast, 2018 - 2030
  • Fig. 29 Autonomic neuropathy market estimates and forecast, 2018 - 2030
  • Fig. 30 Proximal neuropathy market estimates and forecast, 2018 - 2030
  • Fig. 31 Mononeuropathy market estimates and forecast, 2018 - 2030
  • Fig. 32 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 33 Home healthcare market estimates and forecast, 2018 - 2030
  • Fig. 34 Other end users market estimates and forecast, 2018 - 2030
  • Fig. 35 Diabetic neuropathy management market: End use movement analysis
  • Fig. 36 Diabetic neuropathy management market: End use outlook and key takeaways
  • Fig. 37 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 38 Home healthcare market estimates and forecast, 2018 - 2030
  • Fig. 39 Others end users market estimates and forecast, 2018 - 2030
  • Fig. 40 Global diabetic neuropathy management market: Regional movement analysis
  • Fig. 41 Global diabetic neuropathy management market: Regional outlook and key takeaways
  • Fig. 42 North America
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030
  • Fig. 44 U.S.
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 46 Canada
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 48 Mexico
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 50 Europe
  • Fig. 51 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 52 UK
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 56 France
  • Fig. 57 France market estimates and forecasts, 2018 - 2030
  • Fig. 58 Italy
  • Fig. 59 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 60 Spain
  • Fig. 61 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 62 Denmark
  • Fig. 63 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 64 Sweden
  • Fig. 65 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 66 Norway
  • Fig. 67 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 68 Asia Pacific
  • Fig. 69 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 70 China
  • Fig. 71 China market estimates and forecasts, 2018 - 2030
  • Fig. 72 Japan
  • Fig. 73 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 74 India
  • Fig. 75 India market estimates and forecasts, 2018 - 2030
  • Fig. 76 Thailand
  • Fig. 77 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 78 South Korea
  • Fig. 79 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 80 Australia
  • Fig. 81 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 82 Latin America
  • Fig. 83 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 84 Brazil
  • Fig. 85 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 86 Mexico
  • Fig. 87 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 88 Argentina
  • Fig. 89 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 90 Middle East and Africa
  • Fig. 91 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 92 South Africa
  • Fig. 93 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 94 Saudi Arabia
  • Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 96 UAE
  • Fig. 97 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 98 Kuwait
  • Fig. 99 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 100 Market share of key market players - Diabetic neuropathy management market